Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)

NCT03634800 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Lack of patient accruals.

Conditions

Multiple Myeloma

Interventions

DRUG: Nivolumab 240mg
RADIATION: Radiation therapy

Sponsor

Weill Medical College of Cornell University